SEC Form 4 · accession 0001209191-15-078179
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ian F Smith
Officer — EVP & CFO
Period of report
Oct 30, 2015
Accepted (ET)
Nov 3, 2015 · 6:03 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Oct 30, 2015 | S | 2,800 | $124.95 | D | 115,334 | D | |
| Common StockF2,F4 | Oct 30, 2015 | S | 4,865 | $125.98 | D | 110,469 | D | |
| Common StockF2,F5 | Oct 30, 2015 | S | 2,685 | $126.62 | D | 107,784 | D | |
| Common Stock | holding | — | — | — | 5,306 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to Mr. Smith's company approved trading plan under Rule 10b5-1.
- F2Mr. Smith undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $124.95 (range $124.33 to $125.30).
- F4Open market sales reported on this line occurred at a weighted average price of $125.98 (range $125.33 to $126.28).
- F5Open market sales reported on this line occurred at a weighted average price of $126.62 (range $126.34 to $126.93).